Tulsa's First Provider of FDA-Approved Spravato® (Esketamine) Therapy
Spravato Nasal Spray for Treatment-Resistant Depression
If you’ve tried multiple antidepressants without relief, Spravato® may offer a new path forward. Mind Rejuvenation is proud to provide Spravato® (esketamine) CIII nasal spray, the first FDA-approved ketamine-derived treatment covered by insurance for treatment-resistant depression (TRD).
What is Spravato?
Spravato® is a prescription nasal spray designed for adults diagnosed with Major Depressive Disorder (MDD) who haven’t responded to at least two other antidepressant treatments. It’s also approved for individuals experiencing suicidal thoughts or behaviors in the context of depression.
Unlike traditional antidepressants, Spravato® works differently—targeting NMDA receptors in the brain to help restore chemical balance. Administered under medical supervision, it’s part of a comprehensive treatment plan that includes ongoing support and monitoring.
Spravato® is not a pain reliever or anesthetic. It is not intended for use in children or as a substitute for hospitalization when needed.

Benefits of Spravato
What to Expect During Treatment
Your first visit includes a full consultation and medical screening. If Spravato is right for you, we’ll guide you through each step—from insurance approval to your first dose. Sessions typically last 2 hours and include post-treatment monitoring.